Global Leading Market Research Publisher QYResearch announces the release of its latest report “Fisetin API – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fisetin API market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Fisetin API was estimated to be worth US28millionin2025andisprojectedtoreachUS28millionin2025andisprojectedtoreachUS85 million by 2032, growing at a CAGR of 17.2% from 2026 to 2032. For longevity researchers, nutraceutical developers, and clinical trial sponsors, the core business imperative lies in utilizing Fisetin API (active pharmaceutical ingredient) that addresses the critical need for a potent, natural flavonol (plant-derived polyphenol) with demonstrated senolytic activity (selectively eliminates senescent (aging) cells), anti-inflammatory (inhibits NF-κB, COX-2, reduces IL-6, TNF-α), antioxidant (scavenges free radicals, activates Nrf2 pathway), neuroprotective (protects against Alzheimer’s, Parkinson’s, reduces amyloid-beta aggregation), and analgesic (pain relief) properties. Fisetin is naturally found in strawberries (highest concentration), apples, persimmons, grapes, onions, cucumbers, and mangoes. The API is manufactured via extraction from plant sources (primarily strawberry hulls or Rhus succedanea (wax tree) or Euonymus alatus (winged spindle)) followed by purification, or via chemical synthesis. Key applications: anti-inflammatory (chronic inflammatory conditions, arthritis, rheumatism, inflammatory bowel disease (IBD)), pain relief (neuropathic pain, inflammatory pain, osteoarthritis), and others (senolytic therapy (clears senescent cells, improves healthspan, delays age-related diseases), neuroprotection (Alzheimer’s, Parkinson’s, Huntington’s, multiple sclerosis), cardiovascular protection (reduces oxidative stress, improves endothelial function), metabolic health (improves insulin sensitivity, reduces blood glucose), skin health (protects against UV damage, reduces photoaging), cancer research (induces apoptosis in cancer cells, chemosensitization)). Purity grades: 98% (standard commercial grade for research and early-stage nutraceuticals) and 99% (high purity, for clinical trials, pharmaceutical research, premium supplements). Key suppliers: INDOFINE Chemical Company, Inc (US), Cayman Chemical (US), Chemodex Ltd (US), Selleck Chemicals (US/China), LGC Group (UK/Germany), Hangzhou Longshine Bio-Tech Co., Ltd (China), Xi’an Saiyang Biotechnology Co., Ltd (China). The market is currently driven by growing interest in senolytics and longevity science, with fisetin emerging as one of the most promising natural senolytic compounds alongside quercetin, dasatinib, and navitoclax.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5975749/fisetin-api
1. Market Drivers: Senolytic Research Boom, Longevity Supplements, and Clinical Trials
Several powerful forces are driving the Fisetin API market:
Senolytic drug discovery and longevity research – Fisetin, quercetin, dasatinib, navitoclax are lead senolytic compounds. Multiple human clinical trials (NCT NCT number) (IPF (idiopathic pulmonary fibrosis), osteoarthritis, frailty, Alzheimer’s, diabetic kidney disease). Fisetin shows higher senolytic potency (EC50) than quercetin in some assays. Mayo Clinic, Scripps, Buck Institute research. Investor and public interest in longevity (healthspan extension).
Aging population and preventative health – Global population ≥65 years (800 million+). Senolytics target age-related diseases (Alzheimer’s, osteoarthritis, atherosclerosis, macular degeneration). Fisetin clinical trial (2024-2025) for frailty (NCT04815902). Lifespan.io crowdfunding.
Natural, over-the-counter availability – Fisetin supplements available without prescription (Amazon, iHerb, Life Extension, Double Wood, Renue by Science, Alive by Science). Senolytic protocols intermittent (2-3 days/week or month). Consumer demand outpaces clinical evidence.
Recent market data (December 2025): According to Global Info Research analysis, 98% purity fisetin API dominates with approximately 65% revenue share (research, early nutraceutical). 99% purity holds 30% share (clinical trials, pharma-grade). Others 5% share. Anti-inflammatory applications (research, supplements) largest segment (45% share). Pain relief (neuropathic, osteoarthritis) 30% share. Senolytic and anti-aging applications fastest-growing (20%+ CAGR). North America (US longevity research, clinical trials) largest market (55% share). Europe 25% share. Asia-Pacific (China, Japan) 20% share (fastest-growing 20-22% CAGR). Cayman Chemical, Selleck Chemicals, INDOFINE Chemical, LGC Group leaders; Chinese suppliers (Hangzhou Longshine, Xi’an Saiyang) gaining share.
2. Product Specifications and Bioactivity
| Purity Grade | Standardization (HPLC) | Typical Price (USD/g) | Primary Applications | Share |
|---|---|---|---|---|
| 98% | ≥98% by HPLC | US$50-200 | Research, early-stage nutraceuticals, pre-clinical studies | ~65% |
| 99% | ≥99% by HPLC | US$100-500 | Clinical trials, pharmaceutical-grade, premium supplements | ~30% |
Key specifications: CAS number (528-48-3). Molecular formula (C15H10O6). Molecular weight (286.24 g/mol). Appearance (yellow powder). Melting point (330-332°C). Solubility (practically insoluble in water, soluble in DMSO, ethanol, PEG). Mechanisms of action: senolytic (induces apoptosis in senescent cells via PI3K/AKT, BCL-2 family modulation), antioxidant (Nrf2 activation, free radical scavenging), anti-inflammatory (NF-κB inhibition, COX-2 downregulation), neuroprotective (BDNF (brain-derived neurotrophic factor) upregulation, reduces amyloid-beta, α-synuclein aggregation). Bioavailability: low (≈10-44% in animal studies, human data pending), often formulated with cyclodextrins, liposomes, or phytosome for enhancement. Stability (2-3 years, dry, dark, cool). Storage (-20°C recommended for long-term). Pharmaceutical standards: USP (United States Pharmacopeia) monograph not yet official; in-house standards.
Exclusive observation (Global Info Research analysis): Fisetin API market is high-value, low-volume (US28M,2025)comparedtoquercetin(US28M,2025)comparedtoquercetin(US285M) due to higher cost (US50−500/gvsUS50−500/gvsUS30-80/kg) and limited natural supply (strawberry hulls, wax tree). Unlike quercetin (commodity), fisetin is premium research compound positioned for senolytic clinical trials. Cayman Chemical (US) and Selleck Chemicals (China/US) dominate research-grade; LGC Group (UK); INDOFINE Chemical (US); Chemodex (US). Chinese suppliers (Hangzhou Longshine, Xi’an Saiyang) produce for domestic and export at lower cost (30-50% less than US/European). No GRAS (Generally Recognized as Safe) status yet, limiting dietary supplement market. Life Extension, Double Wood, Renue by Science sell fisetin supplements (99% purity, 100mg capsules) retail US$30-60 per bottle for early adopters. Clinical trial outcomes will determine mass-market adoption.
User case – pre-clinical mouse study (December 2025): University aging research lab (US) uses 98% fisetin (Cayman Chemical) for senolytic study in aged mice (24-months old). Dose 50mg/kg (IP injection) weekly. Measures senescent cell markers (p16, p21, senescence-associated β-galactosidase), frailty index (walking speed, grip strength, endurance).
User case – human senolytic supplement (January 2026): Longevity enthusiast (California, 55yo) takes fisetin supplement (99% purity, 500mg oral capsules) for 2 consecutive days monthly (senolytic protocol). Purchased online (Double Wood, Renue by Science). Reports subjective improvement in joint pain (possibly placebo). Purchases via Amazon.
3. Key Challenges and Technical Difficulties
Low bioavailability (estimated 10-44%) – Fisetin poorly absorbed. Liposomal formulation, cyclodextrin complex, or phytosome required for meaningful systemic levels. Most supplements use unformulated powder.
Limited long-term human safety data – Long-term (>1 year) human clinical trials not yet published. Potential off-target effects unknown. Regulation as dietary supplement (US) (no FDA approval required) but product liability risk.
Technical difficulty – high cost per dose (US$2-20 per day): Senolytic protocol (500mg fisetin 2 days/month = 1g/month) still affordable. Daily dosing expensive.
Technical development (October 2025): Life Extension launched “Fisetin + Apigenin + Luteolin” combination senolytic formula (targets multiple senescence pathways). Retail US$59.95 per 30 capsules (500mg fisetin + 250mg apigenin + 250mg luteolin). Positioned as “Senolytic Activator.”
4. Competitive Landscape
Key players include: INDOFINE Chemical Company, Inc (US – research-grade, small molecule), Cayman Chemical (US – global leader in research biochemicals), Chemodex Ltd (US), Selleck Chemicals (US/China – research compounds), LGC Group (UK/Germany – reference standards), Hangzhou Longshine Bio-Tech Co., Ltd (China – API manufacturer), Xi’an Saiyang Biotechnology Co., Ltd (China – API manufacturer). Cayman Chemical dominates research sales (academic, biotech). Selleck Chemicals strong in Asia.
Regional dynamics: North America (Cayman, INDOFINE, Chemodex) largest market (research). Europe (LGC). China (Hangzhou Longshine, Xi’an Saiyang) low-cost manufacturing. API exported for supplement manufacturing (US, Europe). Clinical trial-grade from Cayman, Selleck, LGC.
5. Outlook
Fisetin API market will grow at 17.2% CAGR to US$85 million by 2032, driven by senolytic clinical trial results, longevity consumer demand, and aging population. Technology trends: liposomal fisetin (enhanced bioavailability), combination senolytic formulas (fisetin + quercetin + dasatinib), and nanoparticle delivery. Clinical trial news catalysts (Mayo Clinic, Scripps). China manufacturing cost advantage. Consumer supplements will grow rapidly if safety and efficacy confirmed.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
